From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Legal status ?
CAS number 153322-05-5
ATC code None
PubChem CID 9794203
Chemical data
Formula C13H14N2 
Mol. mass 198.26 g/mol

Lanicemine (AZD6765) is an NMDA antagonist developed by AstraZeneca,[1] which was being studied for the management of severe and treatment-resistant depression.[2] It was originally developed as a neuroprotective agent, but was redeveloped as an antidepressant following the observation that the anesthetic drug ketamine has potent antidepressant effects, but also has hallucinogenic side effects which make it unsuitable for use as an antidepressant in most circumstances. Lanicemine is a low-trapping NMDA receptor antagonist which has been found in human trials to have similar rapid-acting antidepressant effects to ketamine, but with little or no psychotomimetic side effects.[3] Its development was terminated in 2013.[4]

See also[edit]


  1. ^ US 6518432, Melvyn E. Giles, "Process" 
  2. ^ "AstraZeneca Annual Report and Form 20-F Information 2012". 
  3. ^ Zarate, C. A.; Mathews, D.; Ibrahim, L.; Chaves, J. F.; Marquardt, C.; Ukoh, I.; Jolkovsky, L.; Brutsche, N. E.; Smith, M. A.; Luckenbaugh, D. A. (2012). "A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression". Biological Psychiatry 74 (4): 257–264. doi:10.1016/j.biopsych.2012.10.019. PMC 3594049. PMID 23206319.  edit
  4. ^ Flowers, Sophie. "Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company". Retrieved 6 February 2014.